Jupiter Neurosciences, Inc. Common Stock (JUNS) - Total Liabilities
Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) has total liabilities worth $2.52 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Jupiter Neurosciences, Inc. Common Stock cash conversion from operations to assess how effectively this company generates cash.
Jupiter Neurosciences, Inc. Common Stock - Total Liabilities Trend (2019–2024)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See Jupiter Neurosciences, Inc. Common Stock book value and equity for net asset value and shareholders' equity analysis.
Jupiter Neurosciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Jupiter Neurosciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nuvotec
KQ:060260
|
Korea | ₩32.17 Billion |
|
TJGC Group Limited
NASDAQ:TJGC
|
USA | $2.18 Million |
|
NextEye Co. Ltd
KQ:137940
|
Korea | ₩40.27 Billion |
|
Skycorp Solar Group Limited Ordinary Shares
NASDAQ:PN
|
USA | $18.76 Million |
|
Turk Ilac ve Serum Sanayi AS
IS:TRILC
|
Turkey | TL4.21 Billion |
|
Inepar S.A. Indústria e Construções
SA:INEP3
|
Brazil | R$2.36 Billion |
|
Sarama Resource
V:SWA
|
Canada | CA$1.62 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Jupiter Neurosciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Jupiter Neurosciences, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 43.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.98 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jupiter Neurosciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jupiter Neurosciences, Inc. Common Stock (2019–2024)
The table below shows the annual total liabilities of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.03 Million | -65.88% |
| 2023-12-31 | $5.95 Million | -19.38% |
| 2022-12-31 | $7.38 Million | +26.26% |
| 2021-12-31 | $5.85 Million | +37.18% |
| 2020-12-31 | $4.26 Million | -15.16% |
| 2019-12-31 | $5.02 Million | -- |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phas… Read more